WHO Drug Information Vol. 16, No. 2, 2002
(2002; 91 pages) View the PDF document
Table of Contents
Open this folder and view contentsHerbal Medicines
Open this folder and view contentsCurrent Topics
Open this folder and view contentsGood Clinical Practices
Close this folderSafety Information
View the documentStatins: rhabdomyolysis and myopathy
View the documentTamoxifen and risks of thromboembolic events
View the documentOral contraceptives and risk of cervical cancer
View the documentHIV-associated lipodystrophy syndrome overview
Open this folder and view contentsRegulatory Action
Open this folder and view contentsEssential Medicines
Open this folder and view contentsRecent Publications and Sources of Information
View the documentProposed International Nonproprietary Names: List 87
 

Tamoxifen and risks of thromboembolic events

Tamoxifen is already a widely used hormonal treatment in women following treatment for early and advanced breast cancer. Now, in addition to its use as a treatment in cancer, preliminary results from the International Breast Cancer Intervention Study (IBIS) provide evidence for the use of tamoxifen to prevent breast cancer in healthy women at high risk. The results so far show that the incidence of breast cancer has been reduced by one-third in women at high risk, compared to women taking placebo. However, the study also indicated that tamoxifen can increase the risk of thromboembolism, particularly during and immediately after major surgery or periods of immobility. The Department of Health in the United Kingdom has communicated the following information.

1. The benefits for women being treated for breast cancer with tamoxifen outweigh the risks. It is important that women taking the drug as a treatment continue to do so.

2. There is evidence of some increase in risk from thromboembolism with tamoxifen especially during and immediately after major surgery or periods of immobility. Patients should be made aware of the symptoms of venous thromboembolism and if they have any sudden onset of breathlessness they should consult their doctor immediately.

2. The IBIS study gives evidence of the preventative action of tamoxifen in breast cancer. However this is not a use of tamoxifen that has yet been approved except in the context of clinical trials.


Reference: Urgent Communication from Chief Medical Officer, 27 March 2002. http://www.mca.gov.uk

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018